Compare Angi Inc (ANGI) vs Cassava Sciences Inc (FLNA) Price & Performance

ANGI trades at $4.59, down 5.17% on the day, reflecting ongoing operational challenges. The stock is in a bearish technical trend, with revenue declining from $1.03B in 2025 to a projected $993M in 2026. Recent Q2 2026 earnings missed expectations significantly, with an EPS of -$5.7 versus an expected $0.1333, highlighting deep profitability issues. Negative net income margins and cash flow concerns persist, though valuation ratios like P/S of 0.19 and P/B of 0.27 appear low.

The outlook remains cautious due to accelerating user churn, revenue declines, and lack of clear catalysts. Analyst consensus is a Hold with a $7.00 price target, but risks include ongoing fraud investigations, competitive pressures, and negative cash flow trends. Upside potential exists if the company stabilizes its platform, but current fundamentals suggest continued headwinds for shareholder value.

FLNA trades at $0.9973, up 0.23% with a bearish technical signal despite recent earnings beats. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though cash burn improved from -$33M to -$30M projected for 2026. Analyst consensus is strongly bullish with 8 buy ratings versus 4 hold ratings.

The outlook remains challenging due to persistent losses and negative cash flow, but analyst optimism and continued progress in TSC-related epilepsy therapies provide potential catalysts. Key risks include execution challenges in clinical development and the company's ability to secure additional funding.